Neuropeptide Y (NPY) has been found to play a role in the pathomechanism of both anxiety and depression. Thus, NPY is a promising candidate in the investigation of the clinical phenotype of "anxious depression". Five NPY gene variants were investigated for an influence on antidepressant treatment response in a sample of 256 patients with depression. Additionally, NPY gene impact on amygdala activation during facial emotion processing was analyzed in a subsample of 35 depressed patients.Particularly in anxious depression, the less active NPY rs16147-399C allele conferred slow response after 2. weeks and failure to achieve remission after four weeks of treatment. The rs16147 C allele was further associated with stronger bilateral amygdala activation in response to threatening faces in an allele-dose fashion.The present results point towards a possible influence of functional NPY gene variation on antidepressant treatment response in anxious depression, potentially conveyed by altered emotional processing. © 2009 Elsevier B.V. and ECNP.
CITATION STYLE
Domschke, K., Dannlowski, U., Hohoff, C., Ohrmann, P., Bauer, J., Kugel, H., … Baune, B. T. (2010). Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression. European Neuropsychopharmacology, 20(5), 301–309. https://doi.org/10.1016/j.euroneuro.2009.09.006
Mendeley helps you to discover research relevant for your work.